Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the USA / NCT07872072
Starting soon Not applicable

HomeCare Medication Management for People With Dementia

NCT07872072 · tracked via the Priya Life Science USA tracker
Sponsor
HiDO Technologies
Phase
Not applicable
Started
2027-01-01
Last updated
2026-10-13

Condition(s) studied

DementiaAlzheimer's Disease and Related Dementias

Investigational drug(s) / intervention(s)

HomeCare

HomeCare: An automated, secure, AI driven medication delivery and observation platform to maximize therapy compliance, provide continuous medication monitoring and outcomes for individuals impacted by AD/ADRD.

Study summary

This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.

HomeCare is an internet-connected medication management device that can automate medication dispensing, monitor medication use, and provide alerts to caregivers. The system is integrated with a Pharmacy Distribution System designed to track medications from pharmacy delivery through use in the home.

A total of 120 participants with dementia will be randomly assigned to one of two groups. One group will use the HomeCare system, while the other group will continue using standard medication management methods, such as pill bottles or blister packs. Participants will be followed for 12 months. The main outcome is medication adherence. The study will also examine hospitalizations and emergency room visits, cognitive function, caregiver burden, quality of life, satisfaction, and changes in medication-management behavior. Caregivers will also participate in surveys and study assessments. The study is intended to determine whether HomeCare can improve medication management and support both people living with dementia and their caregivers.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 65 years or older. * Living with dementia, Alzheimer's Disease, or Alzheimer's Disease Related Dementias (AD/ADRD) according to standardized diagnostic criteria. * Capable of providing informed consent or have a legally authorized representative available to consent on their behalf. * Access to a smartphone, tablet, or computer with internet connectivity. Able to communicate in either English or Spanish. Exclusion Criteria: * Significant comorbidities or medical conditions that could interfere with participation or severe cognitive function. * History of severe psychiatric illness or substance abuse disorder. * Recent participation in other clinical trials targeting cognition or dementia. * Unwillingness or inability to comply with study procedures. * Residence in a long-term care facility or institutional setting that may limit access to the home-based study intervention.

Primary outcome measure(s)

  • Medication Adherence — 12 months
    Medication adherence will be assessed using the Medication Adherence Rating Scale (MARS) and Proportion of Days Covered (PDC). The HomeCare system will track adherence through its automated logging of medication usage and AI-powered monitoring algorithms.

Trial sites (1)

FacilityCityRegionStatus
University of California, Davis Davis California

More HiDO Technologies trials in the USA

Preventing Medication Mismanagement in People Living With Dementia Recruiting

Other trials for the same condition

Making Connections Thru Music Recruiting
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD) Active, not recruiting
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias Starting soon
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy Recruiting
Phase I Human Analytics (HALO) Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07872072 on ClinicalTrials.gov ↗ ← All trials in the USA